Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Drug Review: US FDA Approves More ANDAs Than It Receives For First Time Since Early 2016

Executive Summary

Among the 61 approvals in February appear to be ANDAs from the official GDUFA backlog, which have been pending for more than four years.

You may also be interested in...

US Generic Reviews: Would Pre-Submission Meetings Be Better Than Six-Month Priority Review?

Lawmakers inquire about expanding pre-submission meetings to include non-complex priority ANDAs, suggesting it could be another way to help deal with drug pricing issues.

Generic Drug Review At US FDA: Has Submission Rush Ended Or Just Paused?

Excitement to get a 10-month ANDA review may have waned in January as submissions plummet, but can approvals keep up?

ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System

As more generic applications arrive, Office of Generic Drugs staff may have a tougher time reaching review goals.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts